- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma
Yes for leronlimab! (Twitter) - Aug 12, 2020
- |||||||||| Selzentry (maraviroc) / ViiV Healthcare, Vyrologix (leronlimab) / CytoDyn, Vyera Pharma
Journal: Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme. (Pubmed Central) - Aug 11, 2020 CCL5/CCR5 is suggested to be an excellent new target for glioblastoma therapy. The molecular mechanisms, by which chemoattractant and receptor respond within the complex tissue microenvironment to promote cancer stem cells and tumour heterogeneity, should be considered in forthcoming studies.
- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma, amfAR
Enrollment closed, Trial completion date, Trial primary completion date: Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19 (clinicaltrials.gov) - Aug 10, 2020 P2, N=86, Active, not recruiting, The molecular mechanisms, by which chemoattractant and receptor respond within the complex tissue microenvironment to promote cancer stem cells and tumour heterogeneity, should be considered in forthcoming studies. Recruiting --> Active, not recruiting | Trial completion date: Apr 2021 --> Aug 2021 | Trial primary completion date: Dec 2020 --> Jul 2020
- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma
LERONLIMAB (Twitter) - Jul 23, 2020
- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma
Leronlimab tho (Twitter) - Jul 21, 2020
- |||||||||| Vyrologix (leronlimab) / CytoDyn, Vyera Pharma
#Leronlimab @CytoDyn (Twitter) - Jul 1, 2020
|